More aggressive scrutiny of life science deals – but is there a problem that needs solving?

Competition authorities on either side of the Atlantic and beyond are signalling greater scrutiny of pharmaceutical mergers, with a view to protecting innovation. Baker McKenzie attorneys Fiona Carlin, Anthony Gamble, Dan Graulich and Yana Ermak consider the justifications for this tougher approach and explore the potential chilling effect it might have.

Get unlimited access to all Global Competition Review content